---
schema_version: "secwatch.filing_event.v1"
accession: "0001847903-24-000052"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:34:04.732747+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Centessa reports Q4 net loss $36.8M; cash $256.5M; SerpinPC and ORX750 milestones on track

## Summary
- Net loss of $36.8M for Q4 2023 vs $43.2M YoY; full-year net loss $151.1M vs $216.2M.
- Cash, equivalents and ST investments $256.5M at Dec 31, 2023; plus $9.7M ATM proceeds in Jan 2024; funding into 2026.
- SerpinPC PRESent-2 Part 1 interim analysis planned in 2024; Part 1 data at medical conference late 2024/early 2025.
- ORX750 IND clearance targeted; clinical proof-of-concept data in sleep-deprived healthy volunteers expected in 2024.
- Phase 2a SerpinPC data showed 96% median all-bleed ABR reduction with no thromboembolic events to date.

## SEC filing metadata
- accession: 0001847903-24-000052
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000184790324000052/0001847903-24-000052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000184790324000052/cnta-20240328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847903-24-000052
- JSON: https://secwatch.observer/filing/0001847903-24-000052.json
- Plain text: https://secwatch.observer/filing/0001847903-24-000052.txt

## Key facts
- Earnings Releases
  Centessa Pharmaceuticals plc reported financial results for the fourth quarter and full-year ended December 31, 2023.
  - Period: the fourth quarter and full-year ended December 31, 2023
  - Result: reported results
  source text: Centessa Pharmaceuticals plc (the "Company") announced its financial results for the quarter ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847903/000184790324000052/0001847903-24-000052-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.